Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Sep. 30, 2013 | Oct. 24, 2013 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | LCA VISION INC | |
Document Type | 10-Q | |
Current Fiscal Year End Date | -19 | |
Entity Common Stock, Shares Outstanding | 19,247,765 | |
Amendment Flag | FALSE | |
Entity Central Index Key | 1003130 | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Filer Category | Accelerated Filer | |
Entity Well-known Seasoned Issuer | No | |
Document Period End Date | 30-Sep-13 | |
Document Fiscal Year Focus | 2013 | |
Document Fiscal Period Focus | Q3 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (Unaudited) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Assets | ||
Cash and cash equivalents | $27,129 | $31,653 |
Short-term investments | 1,984 | 2,804 |
Patient receivables, net of allowances of $855 and $1,019, respectively | 3,061 | 2,810 |
Other accounts receivable, net | 666 | 443 |
Prepaid expenses and other | 2,473 | 3,318 |
Total current assets | 35,313 | 41,028 |
Property and equipment, net | 7,289 | 6,380 |
Patient receivables, net of allowances of $552 and $634, respectively | 1,170 | 1,059 |
Other assets | 223 | 501 |
Total assets | 43,995 | 48,968 |
Liabilities and Stockholders' Investment | ||
Accounts payable | 6,461 | 8,046 |
Accrued liabilities and other | 7,099 | 11,930 |
Debt obligations maturing within one year | 751 | |
Total current liabilities | 14,311 | 19,976 |
Long-term insurance reserves, less current portion | 5,651 | 5,741 |
Long-term debt obligations, less current portion | 1,245 | 0 |
Other long-term liabilities | 2,308 | 3,454 |
Stockholders' investment | ||
Common stock ($.001 par value; 25,291,637 shares issued and 19,247,765 and 19,050,504 shares outstanding, respectively) | 25 | 25 |
Contributed capital | 180,500 | 179,543 |
Common stock in treasury, at cost (6,043,872 shares and 6,241,133 shares, respectively) | -110,063 | -111,395 |
Accumulated deficit | -50,509 | -49,053 |
Accumulated other comprehensive income | 527 | 677 |
Total stockholders' investment | 20,480 | 19,797 |
Total liabilities and stockholders' investment | $43,995 | $48,968 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, except Share data, unless otherwise specified | ||
Patient receivables, allowances, current (in Dollars) | $855 | $1,019 |
Patient receivables, allowances, noncurrent (in Dollars) | $552 | $634 |
Common stock, par value (in Dollars per share) | $0.00 | $0.00 |
Common stock, shares issued and 19,247,765 and 19,050,504 shares outstanding, respectively) (in Shares) | 25,291,637 | 25,291,637 |
Common stock, shares outstanding (in Shares) | 19,247,765 | 19,050,504 |
Common stock in treasury, shares (in Shares) | 6,043,872 | 6,241,133 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Revenues | $20,656 | $20,009 | $71,569 | $81,298 |
Operating costs and expenses | ||||
Medical professional and license fees | 4,554 | 4,648 | 15,518 | 19,139 |
Direct costs of services | 9,886 | 10,068 | 29,376 | 33,477 |
General and administrative expenses | 2,791 | 3,037 | 8,847 | 10,151 |
Marketing and advertising | 4,981 | 4,803 | 16,918 | 18,283 |
Depreciation | 516 | 1,223 | 1,555 | 3,743 |
Restructuring and impairment | -5 | 10 | 214 | 47 |
22,723 | 23,789 | 72,428 | 84,840 | |
Gain on sale of assets | 65 | 33 | 180 | 221 |
Operating loss | -2,002 | -3,747 | -679 | -3,321 |
Net investment income and other | 225 | 220 | 676 | 498 |
Loss before taxes on income | -1,777 | -3,527 | -3 | -2,823 |
Income tax (benefit) expense | -217 | 22 | -111 | 70 |
Net (loss) income | -1,560 | -3,549 | 108 | -2,893 |
(Loss) earnings per common share | ||||
Basic (in Dollars per share) | ($0.08) | ($0.19) | $0.01 | ($0.15) |
Diluted (in Dollars per share) | ($0.08) | ($0.19) | $0.01 | ($0.15) |
Weighted average shares outstanding | ||||
Basic (in Shares) | 19,241 | 19,017 | 19,182 | 18,968 |
Diluted (in Shares) | 19,241 | 19,017 | 19,332 | 18,968 |
Other comprehensive income (loss), net of tax: | ||||
Foreign currency translation adjustment | 92 | 189 | -150 | 167 |
Unrealized investment gain | 0 | 0 | 0 | 30 |
Total other comprehensive income (loss), net of tax | 92 | 189 | -150 | 197 |
Comprehensive loss | ($1,468) | ($3,360) | ($42) | ($2,696) |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Net income (loss) | $108 | ($2,893) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
Depreciation | 1,555 | 3,743 |
Provision for loss on doubtful accounts | 388 | 704 |
Loss on sale of investments | 8 | |
Impairment charges | 37 | |
Gain on sale of assets | -180 | -221 |
Stock-based compensation | 957 | 1,531 |
Insurance reserve | -102 | -318 |
Changes in operating assets and liabilities: | ||
Patient accounts receivable | -773 | -1,719 |
Other accounts receivable | -207 | -60 |
Prepaid expenses and other | -108 | 870 |
Accounts payable | -1,585 | -2,660 |
Deferred revenue, net of professional fees | -680 | -1,838 |
Accrued liabilities and other | -3,744 | -2,144 |
Net cash used in operations | -4,371 | -4,960 |
Cash flow from investing activities: | ||
Purchases of property and equipment | -505 | -973 |
Proceeds from sale of assets | 217 | 283 |
Purchases of investment securities | -1,984 | -39,659 |
Proceeds from sale of investment securities | 2,804 | 62,064 |
Net cash provided by investing activities | 532 | 21,715 |
Cash flow from financing activities: | ||
Principal payments on loans | -304 | -4,004 |
Shares repurchased for treasury stock | -231 | -357 |
Proceeds from exercise of stock options | 57 | |
Net cash used in financing activities | -535 | -4,304 |
Net effect of exchange rate changes on cash and cash equivalents | -150 | 167 |
(Decrease) increase in cash and cash equivalents | -4,524 | 12,618 |
Cash and cash equivalents at beginning of period | 31,653 | 18,568 |
Cash and cash equivalents at end of period | $27,129 | $31,186 |
Note_1_Description_of_Business
Note 1 - Description of Business and Accounting Policies | 9 Months Ended |
Sep. 30, 2013 | |
Disclosure Text Block [Abstract] | |
Business Description and Accounting Policies [Text Block] | 1. Description of Business and Accounting Policies |
Description of Business | |
We are a provider of laser vision correction services at our LasikPlus® vision centers. Our vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employ advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. We currently use two suppliers for fixed-site excimer lasers: Abbott Medical Optics and Alcon, Inc. Our vision centers are supported by independent ophthalmologists and credentialed optometrists, as well as other healthcare professionals. The ophthalmologists perform the laser vision correction procedures in our vision centers, and ophthalmologists or optometrists conduct pre-procedure evaluations and post-operative follow-up care in-center. Most of our patients currently receive a procedure called LASIK, which we began performing in the United States in 1995. | |
As of September 30, 2013, we operated 59 LasikPlus® vision centers in the United States: 51 full-service LasikPlus® fixed-site laser vision correction centers and eight pre- and post-operative LasikPlus® satellite centers. Included in those 59 vision centers are five vision centers owned and operated by ophthalmologists who license our trademarks. Beginning in late 2011, we began offering refractive lens and cataract services in certain of our existing markets. | |
Basis of Presentation | |
Our Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all adjustments necessary for a fair presentation of our financial position, results of operations, and cash flows for each period presented. These adjustments are of a normal and recurring nature unless otherwise disclosed herein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations. | |
We derived the Condensed Consolidated Balance Sheet as of December 31, 2012 from audited financial statements, but did not include all disclosures required by U.S. GAAP. These Condensed Consolidated Financial Statements should be read in conjunction with our 2012 Annual Report on Form 10-K. Operating results for the three- and nine-month periods ended September 30, 2013 are not necessarily indicative of the results expected in subsequent quarters or for the year ending December 31, 2013. | |
Use of Estimates | |
The preparation of our Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include allowance for doubtful accounts against patient receivables, insurance reserves, income taxes and enhancement accruals. Although our management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions. | |
Reclassifications | |
We have reclassified certain prior-period amounts in the Condensed Consolidated Balance Sheets to conform to current period presentation. The reclassifications were not material to the Condensed Consolidated Financial Statements. | |
Recent Accounting Pronouncements | |
In February 2013, the Financial Accounting Standards Board (“FASB”) issued new guidance to improve the reporting of reclassifications out of Accumulated Other Comprehensive Income (“AOCI”) and requires the disclosure (either on the face of the financial statements or within the Notes) for significant items reclassified out of AOCI and into net income, for each component of other comprehensive income. The new guidance was effective with the filing of our Quarterly Report on Form 10-Q for the three months ended March 31, 2013, with prospective application required and did not have a material impact on our Condensed Consolidated Financial Statements. | |
Patient Receivables and Allowance for Doubtful Accounts | |
We provide financing to some of our patients, including to those who could not otherwise obtain third-party financing. The terms of the financing usually require the patient to pay an up-front fee which is intended to cover some or all of our variable costs and then, we deduct the remainder of the amount due automatically from the patient’s bank account over a period of 12 to 36 months. We have recorded an allowance for doubtful accounts as a best estimate of the amount of probable credit losses from our patient financing program. Each month, we review the allowance and adjust it based upon our experience with patient financing. We charge-off receivables against the allowance when it is probable that a receivable will not be recovered. Our policy is to reserve for all patient receivables that remain open past their financial maturity date and to provide reserves for patient receivables prior to the maturity date so as to bring patient receivables, net of reserves, down to the estimated net realizable value based on historical collectability rates, recent default activity and the current credit environment. Receivable balances that remain open past their financial maturity amounted to $29,000 and $42,000 at September 30, 2013 and December 31, 2012, respectively. | |
We maintained an allowance for doubtful accounts on our patient receivables of $1.4 million and $1.7 million at September 30, 2013 and December 31, 2012, respectively. During the three and nine months ended September 30, 2013, we wrote-off $287,000 and $751,000, respectively, of receivables against the allowance for doubtful accounts and recovered $36,000 and $91,000, respectively, in receivables previously written off. During the three and nine months ended September 30, 2012, we wrote-off $296,000 and $712,000, respectively, of receivables against the allowance for doubtful accounts and recovered $40,000 and $102,000, respectively, in receivables previously written off. |
Note_2_Investments
Note 2 - Investments | 9 Months Ended |
Sep. 30, 2013 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] | 2. Investments |
Management determines the appropriate classification of securities at the time of purchase and reevaluates such designation as of each balance sheet date. We carry available-for-sale securities at fair value, with temporary unrealized gains and losses, net of tax, reported in accumulated other comprehensive income, a component of stockholders’ investment. The amortized cost of debt securities reflects amortization of premiums and accretion of discounts to maturity computed under the effective interest method. We included this amortization in the caption “Net investment income and other” within the Condensed Consolidated Statement of Operations and Comprehensive Loss. We also included in “Net investment income and other” realized gains and losses on sales of securities and declines in value of securities determined to be other-than-temporary. We base the cost of securities sold upon the specific identification method. We include interest and dividends on securities classified as available-for-sale in net investment income. | |
At September 30, 2013 we held certificates of deposit with an adjusted cost basis and fair value of $2.0 million. We did not recognize any realized or unrealized gains or losses on the sale of investment securities during the three and nine months ended September 30, 2013. At December 31, 2012 we held certificates of deposit with an adjusted cost basis and fair value of $2.8 million. We realized no gains or losses on the sale of investment securities for the three months ended September 30, 2012, and we realized gains of $3,000 and other-than–temporary impairments of $11,000 for the nine months ended September 30, 2012. We recognized unrealized gains of $41,000 and no unrealized losses in accumulated other comprehensive income as of September 30, 2012. No investments were held in an unrealized loss position for greater than 12 months at September 30, 2013 or 2012. |
Note_3_Fair_Value_Measurements
Note 3 - Fair Value Measurements | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||
Fair Value Disclosures [Text Block] | 3. Fair Value Measurements | ||||||||||||||||
U.S. GAAP defines a hierarchy which prioritizes the inputs in measuring fair value. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices for identical assets or liabilities in active markets at the measurement date; Level 2 inputs are observable market-based inputs or unobservable inputs that are corroborated by market data at the measurement date; and Level 3 inputs are unobservable inputs reflecting management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. When applying the fair value principles in valuation of assets and liabilities, we are required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying value of cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term maturity of these instruments. | |||||||||||||||||
At September 30, 2013 we held $2.0 million of certificates of deposit, which were considered a Level 2 asset, and no liabilities measured at fair value on a recurring basis. At December 31, 2012 we held $2.8 million of certificates of deposit, and no liabilities measured at fair value on a recurring basis. The valuation technique used to measure fair value of certificates of deposit was based on observable market data. | |||||||||||||||||
There were no transfers between Level 1 and Level 2 measurements in the three and nine months ended September 30, 2013 and 2012. The following table sets forth the reconciliation of beginning and ending balances for auction rate securities at fair value using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2012 (dollars in thousands). The auction rate securities were redeemed prior to December 31, 2012. | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
30-Sep | September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Balance at beginning of period | $ | - | $ | 923 | $ | - | 902 | ||||||||||
Losses included in earnings | - | - | - | (11 | ) | ||||||||||||
Gains included in other comprehensive income | - | - | - | 32 | |||||||||||||
Balance as of September 30 | $ | - | $ | 923 | $ | - | $ | 923 | |||||||||
Note_4_Income_Taxes
Note 4 - Income Taxes | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Income Tax Disclosure [Abstract] | |||||||||||||||||
Income Tax Disclosure [Text Block] | 4. Income Taxes | ||||||||||||||||
The following table presents the components of our income tax expense for the following periods (dollars in thousands): | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
September 30, | September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Current: | |||||||||||||||||
Federal | $ | (241 | ) | $ | 6 | $ | (186 | ) | $ | 19 | |||||||
State and local | 24 | 16 | 75 | 51 | |||||||||||||
Total Current | (217 | ) | 22 | (111 | ) | 70 | |||||||||||
Deferred: | |||||||||||||||||
Federal | $ | - | $ | - | $ | - | $ | - | |||||||||
State and local | - | - | - | - | |||||||||||||
Total Deferred | - | - | - | - | |||||||||||||
Income tax (benefit) expense | $ | (217 | ) | $ | 22 | $ | (111 | ) | $ | 70 | |||||||
Effective income tax rate | -12.2 | % | 0.6 | % | n/m | 2.5 | % | ||||||||||
Our effective tax rate for the three and nine months ended September 30, 2013 was affected by a full valuation allowance against all of our deferred tax assets, net of deferred tax liabilities. | |||||||||||||||||
As of September 30, 2013 and December 31, 2012, the net deferred tax assets are offset by full valuation allowances because it is not more-likely-than-not that we will realize our deferred tax assets. We did not record the related tax benefits in the United States and state jurisdictions during the three and nine months ended September 30, 2013. Income tax expense for the three and nine months ended September 30, 2013 includes $236,000 of tax benefit due to the statute of limitations lapsing on previously unrecognized tax benefits, offset in part by state taxes in certain jurisdictions and interest in other unrecognized tax benefits. Income tax expense for the three and nine months ended September 30, 2012 includes primarily interest in unrecognized tax benefits and state taxes in certain jurisdictions. | |||||||||||||||||
All interest and penalties related to unrecognized tax benefits are recorded as a component of income tax expense. The total amount of unrecognized tax benefits at September 30, 2013 and December 31, 2012 was $336,000 and $508,000, respectively. It is reasonably possible that the amount of the total unrecognized tax benefits may change in the next 12 months. However, we do not believe that any anticipated change will be material to the Condensed Consolidated Financial Statements. |
Note_5_Earnings_Per_Common_Sha
Note 5 - Earnings Per Common Share | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||
Earnings Per Share [Text Block] | 5. Earnings Per Common Share | ||||||||||||||||
We calculate basic earnings per common share data using the weighted average number of common shares outstanding during the period. Diluted per share data reflects the potential dilution that would occur if common stock equivalents were exercised or converted to common stock but only to the extent that they are considered dilutive to our earnings. The following table is a reconciliation of basic and diluted per share data for the following periods (in thousands, except per share amounts): | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
September 30, | September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Basic | |||||||||||||||||
Net (loss) income | $ | (1,560 | ) | $ | (3,549 | ) | $ | 108 | $ | (2,893 | ) | ||||||
Weighted average shares outstanding | 19,241 | 19,017 | 19,182 | 18,968 | |||||||||||||
Basic (loss) earnings per common share | $ | (0.08 | ) | $ | (0.19 | ) | $ | 0.01 | $ | (0.15 | ) | ||||||
Diluted | |||||||||||||||||
Net (loss) income | $ | (1,560 | ) | $ | (3,549 | ) | $ | 108 | $ | (2,893 | ) | ||||||
Weighted average shares outstanding | 19,241 | 19,017 | 19,182 | 18,968 | |||||||||||||
Effect of dilutive securities | |||||||||||||||||
Restricted stock | - | - | 150 | - | |||||||||||||
Weighted average common shares and potential dilutive shares | 19,241 | 19,017 | 19,332 | 18,968 | |||||||||||||
Diluted (loss) earnings per common share | $ | (0.08 | ) | $ | (0.19 | ) | $ | 0.01 | $ | (0.15 | ) | ||||||
Anti-dilutive options (excluded from diluted net (loss) earnings per share computations) | 139 | 489 | 166 | 363 | |||||||||||||
Anti-dilutive restricted stock units (excluded from diluted net (loss) earnings per share computations) | 38 | - | 25 | - | |||||||||||||
Note_6_StockBased_Compensation
Note 6 - Stock-Based Compensation | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 6. Stock-Based Compensation | ||||||||||||||||
We have stock incentive plans through which employees and directors have been or will be granted stock-based compensation. We recognize compensation expense for the grant date fair value of stock-based awards over the applicable vesting period. The components of our pre-tax stock-based compensation expense, net of forfeitures and associated income tax effect, were as follows (dollars in thousands): | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
September 30, | Sepember 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Stock options | $ | - | $ | 15 | $ | 6 | $ | 46 | |||||||||
Restricted stock | 289 | 434 | 951 | 1,485 | |||||||||||||
$ | 289 | $ | 449 | $ | 957 | $ | 1,531 | ||||||||||
Income tax effect | 113 | 174 | 373 | 594 | |||||||||||||
$ | 176 | $ | 275 | $ | 584 | $ | 937 | ||||||||||
We estimate the fair value of stock options granted using the Black-Scholes option-pricing model. This model requires several assumptions, which we have developed based on historical trends and updated based on current market observations. The accuracy of these assumptions is critical to the estimate of fair value for these equity instruments. | |||||||||||||||||
Our restricted stock unit awards include both time-based awards that vest ratably over three years and restricted stock units that are tied to the achievement of certain financial targets and stock performance criteria and cliff-vest at the end of three years. The financial targets include revenue and adjusted earnings per share measurements. Total stockholder return, the stock performance criteria, is considered a market condition and the fair value of those awards was calculated using a Monte Carlo simulation valuation model, which utilizes Level 3 inputs. |
Note_7_Restructuring_Charges
Note 7 - Restructuring Charges | 9 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Restructuring and Related Activities [Abstract] | |||||||||||||
Restructuring and Related Activities Disclosure [Text Block] | 7. Restructuring Charges | ||||||||||||
At September 30, 2013 and December 31, 2012, we included short-term restructuring reserves of $701,000 and $1.8 million, respectively, in “Accrued liabilities and other” in the Condensed Consolidated Balance Sheets. Long-term restructuring reserves were $100,000 and $327,000 at September 30, 2013 and December 31, 2012, respectively, and were included in “Other long-term liabilities.” The decrease in restructuring reserves relates primarily to lease payments for previously closed vision centers and severance payments during the three and nine months ended September 30, 2013. | |||||||||||||
The following table summarizes the restructuring reserves for the three and nine months ended September 30, 2013 (dollars in thousands): | |||||||||||||
Employee | Contract | Total | |||||||||||
Separation | Termination | ||||||||||||
Costs | Costs | ||||||||||||
Balance at December 31, 2012 | $ | 604 | $ | 1,525 | $ | 2,129 | |||||||
Liabilities recognized | - | 219 | 219 | ||||||||||
Payments | (222 | ) | (451 | ) | (673 | ) | |||||||
Balance at March 31, 2013 | $ | 382 | $ | 1,293 | $ | 1,675 | |||||||
Liabilities recognized | - | - | - | ||||||||||
Payments | (118 | ) | (410 | ) | (528 | ) | |||||||
Balance at June 30, 2013 | $ | 264 | $ | 883 | $ | 1,147 | |||||||
Adjustments to liabilities previously recognized | - | (5 | ) | (5 | ) | ||||||||
Payments | (87 | ) | (254 | ) | (341 | ) | |||||||
Balance as of September 30, 2013 | $ | 177 | $ | 624 | $ | 801 | |||||||
Note_8_Debt
Note 8 - Debt | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Debt Disclosure [Abstract] | |||||||||
Debt Disclosure [Text Block] | 8. Debt | ||||||||
Long-term debt obligations consist of (dollars in thousands): | |||||||||
September 30, | December 31, | ||||||||
2013 | 2012 | ||||||||
Third party debt | $ | 1,996 | $ | - | |||||
Debt obligations maturing within one year | (751 | ) | - | ||||||
Long-term obligations (less current portion) | $ | 1,245 | $ | - | |||||
In April 2013, we purchased excimer lasers for all of our full-service vision centers for $2.3 million. We had previously leased these lasers through a vendor financed transaction. In July 2013 we purchased an additional excimer laser for a licensee center. The terms of the financing provide for monthly payments over a 36-month term at a fixed interest rate of 3.5%. | |||||||||
The financing agreement does not contain any financial covenants and is secured by the excimer lasers. The estimated fair value of our debt obligations is $1.9 million based on the present value of the underlying cash flows discounted at our incremental borrowing rate. Within the hierarchy of fair value measurements, this is a Level 3 fair value measurement. The financing agreement represents a significant financing activity which affected recognized assets and liabilities by $2.3 million, but did not result in any cash receipts within the nine-month period ending September 30, 2013. |
Note_9_Accumulated_Other_Compr
Note 9 - Accumulated Other Comprehensive Income | 9 Months Ended | |||||||||
Sep. 30, 2013 | ||||||||||
Disclosure Text Block [Abstract] | ||||||||||
Comprehensive Income (Loss) Note [Text Block] | 9. Accumulated Other Comprehensive Income | |||||||||
The components of accumulated other comprehensive income consisted of the following (dollars in thousands): | ||||||||||
Foreign currency translation adjustment | ||||||||||
Three months ended | Nine months ended | |||||||||
Beginning balance | $ | 435 | $ | 677 | ||||||
Other comprehensive income (loss) before reclassifications | 92 | (150 | ) | |||||||
Balance at September 30, 2013 | $ | 527 | $ | 527 | ||||||
There were no reclassifications out of accumulated other comprehensive income during the three and nine months ended September 30, 2013. |
Note_10_Commitments_and_Contin
Note 10 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | 10. Commitments and Contingencies |
At September 30, 2013, we were party to certain media purchase agreements with remaining commitments that require us to spend an aggregate of $1.3 million over the next two years. | |
From time to time, we are subject to medical malpractice lawsuits arising out of our business. We are insured through our captive insurance company to provide coverage for current claims brought against us. We use the captive insurance company for both primary insurance and excess liability coverage. A number of claims are now pending with our captive insurance company. | |
Our loss reserves are based on our historical claim experience, comparable industry experience and recent trends that would impact the ultimate settlement of claims. However, due to the uncertainties inherent in the determination of these liabilities, the ultimate settlement of claims incurred through September 30, 2013 could differ from the amounts recorded. At September 30, 2013 and December 31, 2012, we maintained insurance reserves of $6.5 million and $6.6 million, respectively, of which $858,000 and $871,000 were classified as current within the caption “Accrued liabilities and other” in the Condensed Consolidated Balance Sheets. Although our insurance reserve reflects our best estimate of the amount of probable loss, we believe the range of loss that is reasonably possible to have been incurred to be approximately $5.0 million to $13.5 million at September 30, 2013. We record any adjustment to these estimates in the period determined. | |
In addition to the above, we are periodically subject to various other claims and lawsuits. We believe that none of these other claims or lawsuits to which we are currently subject, individually or in the aggregate, will have a material adverse effect on our business, financial condition, results of operations or cash flows. |
Accounting_Policies_by_Policy_
Accounting Policies, by Policy (Policies) | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | |
Business Policy [Policy Text Block] | Description of Business |
We are a provider of laser vision correction services at our LasikPlus® vision centers. Our vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employ advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. We currently use two suppliers for fixed-site excimer lasers: Abbott Medical Optics and Alcon, Inc. Our vision centers are supported by independent ophthalmologists and credentialed optometrists, as well as other healthcare professionals. The ophthalmologists perform the laser vision correction procedures in our vision centers, and ophthalmologists or optometrists conduct pre-procedure evaluations and post-operative follow-up care in-center. Most of our patients currently receive a procedure called LASIK, which we began performing in the United States in 1995. | |
As of September 30, 2013, we operated 59 LasikPlus® vision centers in the United States: 51 full-service LasikPlus® fixed-site laser vision correction centers and eight pre- and post-operative LasikPlus® satellite centers. Included in those 59 vision centers are five vision centers owned and operated by ophthalmologists who license our trademarks. Beginning in late 2011, we began offering refractive lens and cataract services in certain of our existing markets. | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation |
Our Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all adjustments necessary for a fair presentation of our financial position, results of operations, and cash flows for each period presented. These adjustments are of a normal and recurring nature unless otherwise disclosed herein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations. | |
We derived the Condensed Consolidated Balance Sheet as of December 31, 2012 from audited financial statements, but did not include all disclosures required by U.S. GAAP. These Condensed Consolidated Financial Statements should be read in conjunction with our 2012 Annual Report on Form 10-K. Operating results for the three- and nine-month periods ended September 30, 2013 are not necessarily indicative of the results expected in subsequent quarters or for the year ending December 31, 2013. | |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates |
The preparation of our Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include allowance for doubtful accounts against patient receivables, insurance reserves, income taxes and enhancement accruals. Although our management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions. | |
Reclassification, Policy [Policy Text Block] | Reclassifications |
We have reclassified certain prior-period amounts in the Condensed Consolidated Balance Sheets to conform to current period presentation. The reclassifications were not material to the Condensed Consolidated Financial Statements. | |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements |
In February 2013, the Financial Accounting Standards Board (“FASB”) issued new guidance to improve the reporting of reclassifications out of Accumulated Other Comprehensive Income (“AOCI”) and requires the disclosure (either on the face of the financial statements or within the Notes) for significant items reclassified out of AOCI and into net income, for each component of other comprehensive income. The new guidance was effective with the filing of our Quarterly Report on Form 10-Q for the three months ended March 31, 2013, with prospective application required and did not have a material impact on our Condensed Consolidated Financial Statements. | |
Receivables Trade and Other Accounts Receivable Allowance for Doubtful Accounts Policy [Policy Text Block] | Patient Receivables and Allowance for Doubtful Accounts |
We provide financing to some of our patients, including to those who could not otherwise obtain third-party financing. The terms of the financing usually require the patient to pay an up-front fee which is intended to cover some or all of our variable costs and then, we deduct the remainder of the amount due automatically from the patient’s bank account over a period of 12 to 36 months. We have recorded an allowance for doubtful accounts as a best estimate of the amount of probable credit losses from our patient financing program. Each month, we review the allowance and adjust it based upon our experience with patient financing. We charge-off receivables against the allowance when it is probable that a receivable will not be recovered. Our policy is to reserve for all patient receivables that remain open past their financial maturity date and to provide reserves for patient receivables prior to the maturity date so as to bring patient receivables, net of reserves, down to the estimated net realizable value based on historical collectability rates, recent default activity and the current credit environment. Receivable balances that remain open past their financial maturity amounted to $29,000 and $42,000 at September 30, 2013 and December 31, 2012, respectively. | |
We maintained an allowance for doubtful accounts on our patient receivables of $1.4 million and $1.7 million at September 30, 2013 and December 31, 2012, respectively. During the three and nine months ended September 30, 2013, we wrote-off $287,000 and $751,000, respectively, of receivables against the allowance for doubtful accounts and recovered $36,000 and $91,000, respectively, in receivables previously written off. During the three and nine months ended September 30, 2012, we wrote-off $296,000 and $712,000, respectively, of receivables against the allowance for doubtful accounts and recovered $40,000 and $102,000, respectively, in receivables previously written off. |
Note_3_Fair_Value_Measurements1
Note 3 - Fair Value Measurements (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Three Months Ended | Nine Months Ended | |||||||||||||||
30-Sep | September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Balance at beginning of period | $ | - | $ | 923 | $ | - | 902 | ||||||||||
Losses included in earnings | - | - | - | (11 | ) | ||||||||||||
Gains included in other comprehensive income | - | - | - | 32 | |||||||||||||
Balance as of September 30 | $ | - | $ | 923 | $ | - | $ | 923 |
Note_4_Income_Taxes_Tables
Note 4 - Income Taxes (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Income Tax Disclosure [Abstract] | |||||||||||||||||
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Current: | |||||||||||||||||
Federal | $ | (241 | ) | $ | 6 | $ | (186 | ) | $ | 19 | |||||||
State and local | 24 | 16 | 75 | 51 | |||||||||||||
Total Current | (217 | ) | 22 | (111 | ) | 70 | |||||||||||
Deferred: | |||||||||||||||||
Federal | $ | - | $ | - | $ | - | $ | - | |||||||||
State and local | - | - | - | - | |||||||||||||
Total Deferred | - | - | - | - | |||||||||||||
Income tax (benefit) expense | $ | (217 | ) | $ | 22 | $ | (111 | ) | $ | 70 | |||||||
Effective income tax rate | -12.2 | % | 0.6 | % | n/m | 2.5 | % |
Note_5_Earnings_Per_Common_Sha1
Note 5 - Earnings Per Common Share (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Basic | |||||||||||||||||
Net (loss) income | $ | (1,560 | ) | $ | (3,549 | ) | $ | 108 | $ | (2,893 | ) | ||||||
Weighted average shares outstanding | 19,241 | 19,017 | 19,182 | 18,968 | |||||||||||||
Basic (loss) earnings per common share | $ | (0.08 | ) | $ | (0.19 | ) | $ | 0.01 | $ | (0.15 | ) | ||||||
Diluted | |||||||||||||||||
Net (loss) income | $ | (1,560 | ) | $ | (3,549 | ) | $ | 108 | $ | (2,893 | ) | ||||||
Weighted average shares outstanding | 19,241 | 19,017 | 19,182 | 18,968 | |||||||||||||
Effect of dilutive securities | |||||||||||||||||
Restricted stock | - | - | 150 | - | |||||||||||||
Weighted average common shares and potential dilutive shares | 19,241 | 19,017 | 19,332 | 18,968 | |||||||||||||
Diluted (loss) earnings per common share | $ | (0.08 | ) | $ | (0.19 | ) | $ | 0.01 | $ | (0.15 | ) | ||||||
Anti-dilutive options (excluded from diluted net (loss) earnings per share computations) | 139 | 489 | 166 | 363 | |||||||||||||
Anti-dilutive restricted stock units (excluded from diluted net (loss) earnings per share computations) | 38 | - | 25 | - |
Note_6_StockBased_Compensation1
Note 6 - Stock-Based Compensation (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] | Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | Sepember 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Stock options | $ | - | $ | 15 | $ | 6 | $ | 46 | |||||||||
Restricted stock | 289 | 434 | 951 | 1,485 | |||||||||||||
$ | 289 | $ | 449 | $ | 957 | $ | 1,531 | ||||||||||
Income tax effect | 113 | 174 | 373 | 594 | |||||||||||||
$ | 176 | $ | 275 | $ | 584 | $ | 937 |
Note_7_Restructuring_Charges_T
Note 7 - Restructuring Charges (Tables) | 9 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Restructuring and Related Activities [Abstract] | |||||||||||||
Restructuring and Related Costs [Table Text Block] | Employee | Contract | Total | ||||||||||
Separation | Termination | ||||||||||||
Costs | Costs | ||||||||||||
Balance at December 31, 2012 | $ | 604 | $ | 1,525 | $ | 2,129 | |||||||
Liabilities recognized | - | 219 | 219 | ||||||||||
Payments | (222 | ) | (451 | ) | (673 | ) | |||||||
Balance at March 31, 2013 | $ | 382 | $ | 1,293 | $ | 1,675 | |||||||
Liabilities recognized | - | - | - | ||||||||||
Payments | (118 | ) | (410 | ) | (528 | ) | |||||||
Balance at June 30, 2013 | $ | 264 | $ | 883 | $ | 1,147 | |||||||
Adjustments to liabilities previously recognized | - | (5 | ) | (5 | ) | ||||||||
Payments | (87 | ) | (254 | ) | (341 | ) | |||||||
Balance as of September 30, 2013 | $ | 177 | $ | 624 | $ | 801 |
Note_8_Debt_Tables
Note 8 - Debt (Tables) | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Debt Disclosure [Abstract] | |||||||||
Schedule of Long-term Debt Instruments [Table Text Block] | September 30, | December 31, | |||||||
2013 | 2012 | ||||||||
Third party debt | $ | 1,996 | $ | - | |||||
Debt obligations maturing within one year | (751 | ) | - | ||||||
Long-term obligations (less current portion) | $ | 1,245 | $ | - |
Note_9_Accumulated_Other_Compr1
Note 9 - Accumulated Other Comprehensive Income (Tables) | 9 Months Ended | |||||||||
Sep. 30, 2013 | ||||||||||
Disclosure Text Block [Abstract] | ||||||||||
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | Foreign currency translation adjustment | |||||||||
Three months ended | Nine months ended | |||||||||
Beginning balance | $ | 435 | $ | 677 | ||||||
Other comprehensive income (loss) before reclassifications | 92 | (150 | ) | |||||||
Balance at September 30, 2013 | $ | 527 | $ | 527 |
Note_1_Description_of_Business1
Note 1 - Description of Business and Accounting Policies (Details) (USD $) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | |
Note 1 - Description of Business and Accounting Policies (Details) [Line Items] | |||||
Number Of Vision Correction Centers Operated | 59 | ||||
Number Of Vision Correction Centers Licensed To Ophthalmologists Who Use Trade Mark | 5 | ||||
Period Over Which Patient Receivables Are Recovered | 9 months | ||||
Receivable Balances That Remain Open Past Maturity Amount | $29,000 | $29,000 | $42,000 | ||
Allowance for Doubtful Accounts Receivable, Write-offs | 287,000 | 296,000 | 751,000 | 712,000 | |
Allowance for Doubtful Accounts Receivable, Recoveries | 36,000 | 40,000 | 91,000 | 102,000 | |
Patient Receivable [Member] | |||||
Note 1 - Description of Business and Accounting Policies (Details) [Line Items] | |||||
Allowance for Doubtful Accounts Receivable | $1,400,000 | $1,400,000 | $1,700,000 | ||
Full Service Centers [Member] | |||||
Note 1 - Description of Business and Accounting Policies (Details) [Line Items] | |||||
Number Of Vision Correction Centers Operated | 51 | ||||
Pre And Post Operative Centers [Member] | |||||
Note 1 - Description of Business and Accounting Policies (Details) [Line Items] | |||||
Number Of Vision Correction Centers Operated | 8 | ||||
Minimum [Member] | |||||
Note 1 - Description of Business and Accounting Policies (Details) [Line Items] | |||||
Period Over Which Patient Receivables Are Recovered | 12 months | ||||
Maximum [Member] | |||||
Note 1 - Description of Business and Accounting Policies (Details) [Line Items] | |||||
Period Over Which Patient Receivables Are Recovered | 36 months |
Note_2_Investments_Details
Note 2 - Investments (Details) (USD $) | 3 Months Ended | 9 Months Ended | |||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | |
Certificates of Deposit [Member] | Certificates of Deposit [Member] | Certificates of Deposit [Member] | |||||
Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | ||||||
Note 2 - Investments (Details) [Line Items] | |||||||
Assets, Fair Value Disclosure | $2,000,000 | $2,800,000 | $2,000,000 | ||||
Available-for-sale Securities, Gross Realized Gain (Loss) | 0 | 0 | |||||
Available-for-sale Securities, Gross Unrealized Gain (Loss) | 0 | 0 | |||||
Available-for-sale Securities, Gross Realized Gains | 0 | 3,000 | |||||
Available-for-sale Securities, Gross Realized Losses | 0 | ||||||
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities | 11,000 | ||||||
Available-for-sale Securities, Gross Unrealized Gain | 41,000 | ||||||
Available-for-sale Securities, Gross Unrealized Loss | 0 | ||||||
Held-to-maturity Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value | $0 | $0 | $0 | $0 |
Note_3_Fair_Value_Measurements2
Note 3 - Fair Value Measurements (Details) (Certificates of Deposit [Member], USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Note 3 - Fair Value Measurements (Details) [Line Items] | ||
Assets, Fair Value Disclosure | $2 | |
Fair Value, Inputs, Level 2 [Member] | ||
Note 3 - Fair Value Measurements (Details) [Line Items] | ||
Assets, Fair Value Disclosure | $2 | $2.80 |
Note_3_Fair_Value_Measurements3
Note 3 - Fair Value Measurements (Details) - Auction Rate Securities at Fair Value Using Significant Unobservable Input (Level 3) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Auction Rate Securities at Fair Value Using Significant Unobservable Input (Level 3) [Abstract] | ||||
Balance at beginning of period | $0 | $923 | $0 | $902 |
Losses included in earnings | 0 | 0 | 0 | -11 |
Gains included in other comprehensive income | 0 | 0 | 0 | 32 |
Balance as of September 30 | $0 | $923 | $0 | $923 |
Note_4_Income_Taxes_Details
Note 4 - Income Taxes (Details) (USD $) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | |
Note 4 - Income Taxes (Details) [Line Items] | |||||
Income Tax Expense (Benefit) | ($217,000) | $22,000 | ($111,000) | $70,000 | |
Unrecognized Tax Benefits | 336,000 | 336,000 | 508,000 | ||
Tax Benefit - Limitations Lapsing [Member] | |||||
Note 4 - Income Taxes (Details) [Line Items] | |||||
Income Tax Expense (Benefit) | ($236,000) | $236,000 |
Note_4_Income_Taxes_Details_Co
Note 4 - Income Taxes (Details) - Components of Income Tax Expense (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Current: | ||||
Federal | ($241) | $6 | ($186) | $19 |
State and local | 24 | 16 | 75 | 51 |
Total Current | -217 | 22 | -111 | 70 |
Deferred: | ||||
Federal | 0 | 0 | 0 | 0 |
State and local | 0 | 0 | 0 | 0 |
Total Deferred | 0 | 0 | 0 | 0 |
Income tax (benefit) expense | ($217) | $22 | ($111) | $70 |
Effective income tax rate | -12.20% | 0.60% | 2.50% |
Note_5_Earnings_Per_Common_Sha2
Note 5 - Earnings Per Common Share (Details) - Reconciliation of Basic and Diluted Earnings Per Share (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Note 5 - Earnings Per Common Share (Details) - Reconciliation of Basic and Diluted Earnings Per Share [Line Items] | ||||
Net income (loss) (in Dollars) | ($1,560) | ($3,549) | $108 | ($2,893) |
Weighted average shares outstanding | 19,241 | 19,017 | 19,182 | 18,968 |
Effect of dilutive securities | ||||
Weighted average common shares and potential dilutive shares | 19,241 | 19,017 | 19,332 | 18,968 |
Diluted (loss) earnings per common share (in Dollars per share) | ($0.08) | ($0.19) | $0.01 | ($0.15) |
Basic (loss) earnings per common share (in Dollars per share) | ($0.08) | ($0.19) | $0.01 | ($0.15) |
Restricted Stock [Member] | ||||
Effect of dilutive securities | ||||
Restricted stock | 0 | 0 | 150 | 0 |
Employee Stock Option [Member] | ||||
Effect of dilutive securities | ||||
Effect of dilutive securities | 139 | 489 | 166 | 363 |
Restricted Stock Units (RSUs) [Member] | ||||
Effect of dilutive securities | ||||
Effect of dilutive securities | 38 | 0 | 25 | 0 |
Note_6_StockBased_Compensation2
Note 6 - Stock-Based Compensation (Details) | 9 Months Ended |
Sep. 30, 2013 | |
Restricted Stock Unit Time Based Awards [Member] | |
Note 6 - Stock-Based Compensation (Details) [Line Items] | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 3 years |
Restricted Stock Unit Performance Based Awards [Member] | |
Note 6 - Stock-Based Compensation (Details) [Line Items] | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 3 years |
Note_6_StockBased_Compensation3
Note 6 - Stock-Based Compensation (Details) - Components of Pre-tax Stock-based Compensation Expense, Net of Forfeitures and Income Tax Effect (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Note 6 - Stock-Based Compensation (Details) - Components of Pre-tax Stock-based Compensation Expense, Net of Forfeitures and Income Tax Effect [Line Items] | ||||
stock-based compensation expense | $289 | $449 | $957 | $1,531 |
Income tax effect | 113 | 174 | 373 | 594 |
Employee Stock Option [Member] | ||||
Note 6 - Stock-Based Compensation (Details) - Components of Pre-tax Stock-based Compensation Expense, Net of Forfeitures and Income Tax Effect [Line Items] | ||||
stock-based compensation expense | 0 | 15 | 6 | 46 |
Restricted Stock [Member] | ||||
Note 6 - Stock-Based Compensation (Details) - Components of Pre-tax Stock-based Compensation Expense, Net of Forfeitures and Income Tax Effect [Line Items] | ||||
stock-based compensation expense | 289 | 434 | 951 | 1,485 |
Stock Based Compensation Expense [Member] | ||||
Note 6 - Stock-Based Compensation (Details) - Components of Pre-tax Stock-based Compensation Expense, Net of Forfeitures and Income Tax Effect [Line Items] | ||||
stock-based compensation expense | $176 | $275 | $584 | $937 |
Note_7_Restructuring_Charges_D
Note 7 - Restructuring Charges (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Restructuring and Related Activities [Abstract] | ||
Restructuring Reserve, Current | $701,000 | $1,800,000 |
Restructuring Reserve, Noncurrent | $100,000 | $327,000 |
Note_7_Restructuring_Charges_D1
Note 7 - Restructuring Charges (Details) - Summary of Restructuring Reserves (USD $) | 3 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 |
Restructuring Cost and Reserve [Line Items] | |||
Restructuring reserve, balance | $1,147 | $1,675 | $2,129 |
Liabilities Recognized | -5 | 0 | 219 |
Payments | -341 | -528 | -673 |
Restructuring reserve, balance | 801 | 1,147 | 1,675 |
Employee Separation Costs [Member] | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring reserve, balance | 264 | 382 | 604 |
Liabilities Recognized | 0 | 0 | 0 |
Payments | -87 | -118 | -222 |
Restructuring reserve, balance | 177 | 264 | 382 |
Contract Termination Costs [Member] | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring reserve, balance | 883 | 1,293 | 1,525 |
Liabilities Recognized | -5 | 0 | 219 |
Payments | -254 | -410 | -451 |
Restructuring reserve, balance | $624 | $883 | $1,293 |
Note_8_Debt_Details
Note 8 - Debt (Details) (USD $) | 4 Months Ended | 9 Months Ended |
In Millions, unless otherwise specified | Apr. 30, 2013 | Sep. 30, 2013 |
Debt Disclosure [Abstract] | ||
Long-term Debt, Gross (in Dollars) | $2.30 | |
Debt Instrument, Term | 36 months | |
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Long-term Debt, Fair Value (in Dollars) | $1.90 | |
Period Over Which Patient Receivables Are Recovered | 9 months |
Note_8_Debt_Details_Longterm_D
Note 8 - Debt (Details) - Long-term Debt Obligations (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Debt Instrument [Line Items] | ||
Debt obligations maturing within one year | ($751) | $0 |
Long-term obligations (less current portion) | 1,245 | 0 |
Third Party [Member] | ||
Debt Instrument [Line Items] | ||
Third party debt | $1,996 | $0 |
Note_9_Accumulated_Other_Compr2
Note 9 - Accumulated Other Comprehensive Income (Details) (USD $) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2013 | Sep. 30, 2013 | |
Disclosure Text Block [Abstract] | ||
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax | $0 | $0 |
Note_9_Accumulated_Other_Compr3
Note 9 - Accumulated Other Comprehensive Income (Details) - Accumulated Other Comprehensive Income (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 |
In Thousands, unless otherwise specified | Accumulated Translation Adjustment [Member] | Accumulated Translation Adjustment [Member] | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Beginning balance | $527 | $677 | $435 | $677 |
Balance at September 30, 2013 | 527 | 677 | 527 | 527 |
Other comprehensive income (loss) before reclassifications | $92 | ($150) |
Note_10_Commitments_and_Contin1
Note 10 - Commitments and Contingencies (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Note 10 - Commitments and Contingencies (Details) [Line Items] | ||
Self Insurance Reserve | $6,500,000 | $6,600,000 |
Self Insurance Reserve, Current | 858,000 | 871,000 |
Marketing Commitments [Member] | ||
Note 10 - Commitments and Contingencies (Details) [Line Items] | ||
Contractual Obligation | 1,300,000 | |
Minimum [Member] | ||
Note 10 - Commitments and Contingencies (Details) [Line Items] | ||
Loss Contingency, Estimate of Possible Loss | 5,000,000 | |
Maximum [Member] | ||
Note 10 - Commitments and Contingencies (Details) [Line Items] | ||
Loss Contingency, Estimate of Possible Loss | $13,500,000 |